CRESCENT BIOPHARMA INC

CBIONASDAQ

🏆 #2330 by market capEarnings Nov 5US Equity

$16.84▼ $0.24 (−1.43%)

Market closed · at close

1h—

24h▼ 1.4%

7d▲ 7.0%

14d▲ 15.1%

30d▲ 6.9%

1y▲ 29.6%

🏦Market Cap

$601M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

52.6x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $16.67 – $16.99
52-Week Range: $8.72 – $27.41
Volume: $3.52B
Avg Volume: $2.61B
Shares Outstanding: 35.7M
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $11M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 52.6x
EPS (TTM): $-12.25
Dividend Yield: —

Why Investors Own CBIO

✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
✓Healthy economics — 75% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$11M▲ +27.4% YoY

Gross Margin (TTM)

74.7%▲ +4.0% YoY

Operating Income (TTM)

$3M▲ +27.4% YoY

Free Cash Flow (TTM)

$3M▲ +27.4% YoY

About CRESCENT BIOPHARMA INC

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

🦦